Phytochemicals in Alzheimer disease: The development of clinical trials

Pharmaceutical Biology

Volumn 42, Issue SUPPL., 2004, Pages 64-73

  Quinn, Joseph ^a,d   Kaye, Jeffrey ^a   Montine, Thomas ^b   Stackman, Robert ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; Antioxidants; Oxidative stress; Polyphenolics

Indexed keywords

AMYLOID BETA PROTEIN; CURCUMIN; GINKGO BILOBA EXTRACT; PTI 00703; UNCARIA TOMENTOSA EXTRACT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; CLINICAL TRIAL; GINKGO BILOBA; HEALTH SURVEY; HUMAN; INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; OXIDATIVE STRESS; PHYTOCHEMISTRY; REVIEW; SEIZURE; TRANSGENIC ANIMAL; UNCARIA TOMENTOSA;

ANIMALIA; GINKGO BILOBA; UNCARIA TOMENTOSA;

EID: 11844305626     PISSN: 13880209     EISSN: None     Source Type: Journal    
DOI: 10.1080/138802090893531     Document Type: Review

References (64)

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000): Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421.
2. Bacskai BJ, Klunk WE, Mathis CA, Hyman BT (2002): Imaging amyloid-beta deposits in vivo. J Cereb Blood Flow Metab 22: 1035-1041.
3. Barkats M, Venault P, Christen Y, Cohen-Salmon C (1995): Effect of long-term treatment with EGb 761 on age-dependent structural changes in the hippocampi of three inbred mouse strains. Life Sci 56: 213-222.
4. Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R (2000): The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 12: 1882-1890.
5. Benzing WC, Wujek JR, Ward EK, Shaffer D, Ashe KH, Younkin SG, Brunden KR (1999): Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol Aging 20: 581-589.
6. Cotman CW, Pike CJ, Copani A (1992): beta-Amyloid neurotoxicity: A discussion of in vitro findings. Neurobiol Aging 13: 587-590.
7. de Leon MJ, Segal S, Tarshish CY, DeSanti S, Zinkowski R, Mehta PD, Convit A, Caraos C, Rusinek H, Tsui W, Saint Louis LA, DeBernardis J, Kerkman D, Qadri F, Gary A, Lesbre P, Wisniewski T, Poirier J, Davies P (2002): Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett 333: 183-186.
8. Emre M, Geula C, Ransil BJ, Mesulam MM (1992): The acute neurotoxicity and effects upon cholinergic axons of intracerebrally injected beta-amyloid in the rat brain. Neurobiol Aging 13: 553-559.
9. Folstein MF, McHugh PR (1975): Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 12: 189-198.
10. Fox NC, Scahill RI, Crum WR, Rossor MN (1999): Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 52: 1687-1689.
11. Frautschy SA, Yang F, Irrizarry M, Hyman B, Said TC, Hsiao K, Cole GM (1998): Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152: 307-317.
12. Galli RL, Shukitt-Hale B, Youdim KA, Joseph JA (2002): Fruit polyphenolics and brain aging: Nutritional interventions targeting age-related neuronal and behavioral deficits. Ann NY Acad Sci 959: 128-132.
13. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. (1995): Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373: 523-527.
14. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA (1998): Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nature Med 4: 827-831.
15. Greenwald P, Milner JA, Anderson DE, McDonald SS (2002): Micronutrients in cancer chemoprevention. Cancer Metastasis Rev 21: 217-230.
16. Hardy J, Selkoe DJ (2002): The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297: 353-356.
17. Harkany T, Hortobagyi T, Sasvari M, Konya C, Penke B, Luiten PG, Nyakas C (1999): Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: Relevance to Alzheimer's disease. ProgNeuropsychopharmacol Biol Psychiatry 23: 963-1008.
18. Hernandez D, Sugaya K, Qu T, McGowan E, Duff K, McKinney M (2001): Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. Neuroreport 12: 1377-1384.
19. Hsiao K (1998): Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp Gerontol 33: 883-889.
20. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996): Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102.
21. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT (1997): APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56: 965-973.
22. Jack CR, Jr, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, Kokmen E (1999): Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52: 1397-1403.
23. Jack CR, Jr, Dickson DW, Parisi JE, Xu YC, Cha RH, O'Brien PC, Edland SD, Smith GE, Boeve BF, Tangalos EG, Kokmen E, Petersen RC (2002): Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 58: 750-757.
24. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mizushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M (1998): Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: A study in Japan. Ann Neurol 44: 17-26.
25. Kaye JA, Swihart T, Howieson D, Dame A, Moore MM, Karnos T, Camicioli R, Ball M, Oken B, Sexton G (1997): Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology 48: 1297-1304.
26. Kuo YM, Emmerling MR, Lampert HC, Hempelman SR, Kokjohn TA, Wood AS, Cotter RJ, Roher AE (1999): High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 257: 787-791.
27. Laakso MP, Soininen H, Partanen K, Lehtovirta M, Hallikainen M, Hanninen T, Helkala EL, Vainio P, Riekkinen PJ, Sr (1998): MRI of the hippocampus in Alzheimer's disease: sensitivity, specificity, and analysis of the incorrectly classified subjects. Neurobiol Aging 19: 23-31.
28. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998): Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448-6453.
29. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF (1997): A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 278: 1327-1332.
30. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM (2001): The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21: 8370-8377.
31. Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, Khan I, Netzer WJ, Xu H, Butko P (2002): Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 99: 12197-12202.
32. Mahmood I (2002): Interspecies scaling: Predicting oral clearance in humans. Am J Ther 9: 35-42.
33. Mattson MP, Chan SL, Duan W (2002): Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol Rev 82: 637-672.
34. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP (2001): Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 304: 102-106.
35. Mohamed AF, Matsumoto K, Tabata K, Takayama H, Kitajima M, Watanabe H (2000): Effects of Uncaria tomentosa total alkaloid and its components on experimental amnesia in mice: Elucidation using the passive avoidance test. J Pharm Pharmacol 52: 1553-1561.
36. Mohs RC, Cohen L (1988): Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacol Bull 24: 627-628.
37. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD (1999a): Increased CSF F2-isoprostane concentration in probable AD. Neurology 52: 562-565.
38. Montine TJ, Markesbery WR, Zackert W, Sanchez SC, Roberts LJ, 2nd, Morrow JD (1999b): The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. Am J Pathol 155: 863-868.
39. Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ, Morrow JD (2002a): Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med 33: 620-626.
40. Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, Terry E, Roberts LJ, 2nd, Kaye JA, Morrow JD (2002b): Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 52: 175-179.
41. Montine TJ, Kaye JA, Montine KS, McFarland L, Morrow JD, Quinn JF (2001): Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch Pathol Lab Med 125: 510-512.
42. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ, 2nd (1995): Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 332: 1198-1203.
43. Morrow JD, Roberts LJ (1997): The isoprostanes: Unique bioactive products of lipid peroxidation. Prog Lipid Res 36: 1-21.
44. Oken BS, Storzbach DM, Kaye JA (1998): The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 55: 1409-1415.
45. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978): Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2: 1457-1459.
46. Pirttila T, Koivisto K, Mehta PD, Reinikainen K, Kim KS, Kilkku O, Heinonen E, Soininen H, Riekkinen P, Sr, Wisniewski HM (1998): Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease. Neurosci Lett 249: 21-24.
47. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ (2002): Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Arch Neurol 59: 972-976.
48. Price DL, Borchelt DR, Sisodia SS (1998): Alzheimer's disease: Genetic studies and transgenic models. Ann Rev Genet 32: 461-493.
49. Quinn J, Camicioli RM, Corbridge E, Dang T, Kaye JA (2000): Rate of brain atrophy in Alzheimer's disease correlates with rate of decline on common clinical measures (abstract). Neurology 54 (Suppl 3): A476.
50. Sandoval M, Okuhama NN, Zhang XJ, Condezo LA, Lao J, Angeles FM, Musah RA, Bobrowski P, Miller MJ (2002): Anti-inflammatory and antioxidant activities of cat's claw (Uncaria tomentosa and Uncaria guianensis) are independent of their alkaloid content. Phytomedicine 9: 325-337.
51. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR (2002): Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10: 24-35.
52. Silbert LC, Moore, Corbridge, EM, Ball, MJ, Murdoch G, Sexton G, Kaye JA (2003): Changes in premorbid brain volume predict AD pathology. Neurology 61: 487-492.
53. Sisodia SS, St George-Hyslop PH (2002): gamma-Secretase, Notch, Abeta and Alzheimer's disease: Where do the presenilins fit in? Nat Rev Neurosci 3: 281-290.
54. Sjogren M, Andreasen N, Blennow K (2003): Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers. Clin Chim Acta 332: 1-10.
55. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, Tabaton M, Perry G (1998): Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70: 2212-2215.
56. Snow A (1999): Neurosharp: A new dietary supplement containing PTI00703 TM for the prevention and treatment of brain amyloidosis associated with Alzheimer's disease and aging. Presentation at Experimental Biology '99, Washington, DC.
57. Snow A, Cummings JA, Castillo GM, Choi PY, Masliah E (2001): PTI-777 treatment causes a potent reduction of amyloid laque burden in a transgenic mouse model of Alzheimer's disease. Society for Neuroscience Abstract 687.2.
58. Spencer DC, Zitzelberger T, Spielman D, Kaye J (2003): MRS in relation to hippocampal volume in the oldest old. Neurology 60: 1194-1196.
59. Stackman R, Eckenstein F, Frei B, Kulhanek D, Nowlin J, Quinn JF (2003) Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Experimental Neurology 184: 510-520.
60. Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, Shoji S (1996): Amyloid-beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci 141: 65-68.
61. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991): Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580.
62. Walker LC, Pahnke J, Madauss M, Vogelgesang S, Pahnke A, Herbst EW, Stausske D, Walther R, Kessler C, Warzok RW (2000): Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly. Acta Neuropathol (Berl) 100: 36-42.
63. Winter E (1991): Effects of an extract of Ginkgo biloba on learning and memory in mice. Pharmacol Biochem Behav 38: 109-114.
64. Yao Z, Drieu K, Papadopoulos V (2001): The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res 889: 181-190.